Despite its controversy, many stem cell research companies have promising technology or methodology with the potential for investors to take a closer look in the area. A recent report by Infiniti Research Limited titled Global Stem Cell Therapy Market 2017-2021, grouped the top growth prospect companies involved in any kind of stem cell therapy-based research.
The International Society for Stem Cell Research defines regenerative medicine as a treatment by administering stem cells, or specific cells that are derived from stem cells in the laboratory; or second, by administering drugs that coax stem cells that are already present in tissues to more efficiently repair the tissue involved.
Regenerative Medicine is defined by the International Society for Stem Cell Research as a treatment that administers stem cells derived from a laboratory or from drugs that coax stem cells already in tissue, to repair organs or tissues that are damaged by disease, aging or trauma.
“Technavio’s analysts forecast the global stem cell therapy market to grow at a CAGR of 36.52% during the period 2017-2021,” read the report.
Here is a look at the top 10 Nasdaq-listed companies included in this report, with a market cap of under $500 million.
- Sangamo Therapeutics (NASDAQ:SGMO)
- Cellular Biomedicine Group (NASDAQ:CBMG)
- Pluristem Therapeutics (NASDAQ:PSTI)
- Athersys (NASDAQ:ATHX)
- Vericel (NASDAQ:VCEL)
- BrainstormCell Therapeutics (NASDAQ:BCLI)
- Caladrius Biosciences (NASDAQ:CLBS)
- Cytori Therapeutics (NASDAQ: CYTX)
- Cesca Therapeutics (NASDAQ:KOOL)
- VistaGen Therapeutics (NASDAQ:VTGN)
Market Cap: 297.67 Million
Originally founded as Sangamo BioSciences, this company seeks to develop new medicines to treat genetic diseases. Over a year the company’s share price has gone down 27.5 percent.
They have seven products in their pipeline, all involved in different stages of trials and research while collaborating with Shire (NASDAQ:SHPG) and Bioverativ (NASDAQ:BIVV) for another three. Recently Sangamo obtained an FDA orphan drug designation for SB-913, a genome editing product candidate for the treatment of MPS II.
Cellular Biomedicine Group
Market Cap: 165.77 Million
This company has its eyes set on China as it hopes to become a leader in the specialty pharmaceutical market for cell therapeutics. Later this year they will open a new facility in Shanghai and expand in Wuxi.
They were recently awarded $2.29 million from the California Institute for Regenerative Medicine for clinical trials of AlloJoin, a stem cell treatment for knee osteoarthritis. Over a one-year period, the share price for Cellular Biomedicine Group has gone down 33.77 percent.
Market Cap: 132.29 Million
This clinical-stage biotherapy product develops cell therapy to treat inflammation, ischemia, hematological disorder, or exposure to radiation. Pluristem develops placenta-derived off-the-shelf products.
This company produces their cells in a one of a kind 3D bioreactor that resembles the environment of the human body, which can generate the cells on a mass scale. Over a one-year period, their share price has gone down 31.38 percent
Market Cap: 125.18 Million
Athersys is a biopharmaceutical focused on their MultiStem program, a cell therapy product with off the shelf administration, meaning to need for the patient to submit their own tissue. It is currently under examination for treating inflammatory and immune, neurological, and cardiovascular diseases.
Over a one-year period, their share price has gone down 47.25 percent. In their latest financial results, their research and development costs went up to 7.1 million total in the fourth quarter of 2016.
Market Cap: 95.72 Million
Vericel bases its treatment in tissue collection from the patient, their two lead products Carticel and Epicel seeking to treat cartilage defects in the knee and patients with burns greater than or equal to 30 percent of total body surface area respectively.
For their fourth quarter, Carticel brought in $12.7 million in revenue while Epicel’s net revenue totaled approximately $3.8 million. Over a one-year period, their share price has gone down 35.23 percent.
Market Cap: 76.42 Million
Thanks to their proprietary technology, BrainstormCell converts mesenchymal stem cells into their own NurOwn therapy platform.
The company is looking to expand NurOwn into the Canadian market by partnering with the Centre for Commercialization of Regenerative Medicine in Toronto. Over a one-year period, BrainStormCell’s share price has gone up 51.27 percent.
Market Cap: 46.90 Million
Caladrius is investigating its lead product candidate CLBS03 to treat recent-onset type 1 diabetes, currently going through a Phase 2 clinical trial. They plan for this treatment to be autologous.
This cell therapy development company’s total revenue for 2016 totaled $35.3 million, a 57 percent increase from 2015. Over a one-year period, the company’s share price has gone up 616.86 percent.
Market Cap: 34.67 Million
Recently the company announced the acquisition of assets from Azaya Therapeutics, such as the ATI-0918 drug candidate and announced it plans to develop a nanoparticle-based therapeutics under the name Cytori Nanomedicine in the areas of oncology and regenerative medicine.
They are currently enrolled in a variety of clinical trials for their pipeline of products. They also sell products in Asia Pacific, Europe, and Japan. Over a one-year period, the company’s share price has gone down 35.26 percent.
Market Cap: 27.70 Million
The company recently announced “encouraging” data from a 24 patient study showing the use of autologous platelet-rich plasma to treat chronic non-healing ulcers. Cesca wants their technology to serve the bio-banking and regenerative medicine market.
Having gone through a recent management shift, the company announced Vivian Liu as its new COO. Over a one-year period, Cesca’s share price has gone down 22.28 percent.
Market Cap: 18.19 Million
This company owns a subsidiary VistaStem, seeks to develop and commercialize new chemical entities with regenerative potential and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.
Currently, VisteStem is working on predicting potential heart toxicity of new chemical entities by combining their human pluripotent stem cell technology platform and CardioSafe 3D a human cardiac cell bioassay system. Over a one-year period, the company’s share price has gone down 74.29 percent.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.